Drug
Ft522
Ft522: highest development phase Phase 1, developed by Fate Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FT522 NCT05950334 | Phase 1 | Relapsed/Refractory B-Cell Lymphoma |
Latest
No recent events.
Follow Ft522 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.